Physician profile
Michael L Shea
NPI 1659530178
$6,356.09
in general payments reported to CMS, 2019-2025
35 companies · $931 in 2025
The $931 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $473 · 2021: $645 · 2022: $1,338 · 2023: $1,173 · 2024: $1,050 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,153.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $904.97 | 2019-2025 | |
| Pfizer INC. | $850.44 | 2019-2025 | |
| Amgen INC. | $711.72 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $711.02 | 2020-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $477.43 | 2019-2025 | Brilinta, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $453.70 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $430.34 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.43 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $216.79 | 2022-2025 | Verquvo, Capvaxive |
| Akcea Therapeutics, INC. | $209.78 | 2019-2020 | |
| Abbott Laboratories | $194.07 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Aveir |
| Boston Scientific Corporation | $77.13 | 2019-2024 | Bodyguardian |
| Bayer Healthcare Pharmaceuticals INC. | $73.11 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $66.16 | 2020-2024 | |
| Esperion Therapeutics, INC. | $55.80 | 2020-2023 | Nexletol |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $52.27 | 2019-2023 | Evkeeza |
| Novo Nordisk INC | $51.11 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bridgebio Pharma, INC. | $50.16 | 2025 | Attruby |
| Tactile Systems Technology INC | $48.39 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Medtronic, INC. | $44.93 | 2022-2025 | Linq II |
| Lundbeck LLC | $41.06 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $35.16 | 2020-2021 | |
| Kestra Medical Technology Services, INC. | $33.84 | 2022-2023 | Assure Wcd |
| Gilead Sciences, INC. | $30.67 | 2019 | |
| Bioventus LLC | $26.33 | 2019 | |
| Biotronik INC. | $23.90 | 2022 | |
| Heartflow, INC. | $21.44 | 2024 | |
| Irhythm Technologies, INC. | $21.22 | 2024 | Zio Monitor, Zio Xt Patch |
| Becton, Dickinson and Company | $19.10 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.98 | 2019 | |
| Bardy Diagnostics, INC. | $16.34 | 2021 | |
| Scpharmaceuticals INC. | $13.56 | 2025 | |
| G Medical Diagnostic Services, INC. | $12.77 | 2022 | |
| Medtronic Vascular, INC. | $12.68 | 2019 | |
| Daxor Corporation | $11.29 | 2024 | Bva-100 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.